Johnson & Johnson (NYSE:JNJ)‘s stock had its “outperform” rating restated by analysts at Leerink Swann in a research report issued on Wednesday, October 18th, MarketBeat Ratings reports. They presently have a $165.00 target price on the stock, up from their previous target price of $150.00. Leerink Swann’s price objective would suggest a potential upside of 16.38% from the company’s current price. Leerink Swann also issued estimates for Johnson & Johnson’s Q4 2017 earnings at $1.69 EPS, FY2017 earnings at $7.25 EPS, Q1 2018 earnings at $1.99 EPS, Q2 2018 earnings at $2.01 EPS, Q3 2018 earnings at $2.18 EPS, Q4 2018 earnings at $1.81 EPS, FY2018 earnings at $8.00 EPS, FY2019 earnings at $8.55 EPS and FY2020 earnings at $9.24 EPS.
JNJ has been the subject of several other reports. Morgan Stanley boosted their price objective on shares of Johnson & Johnson from $135.00 to $140.00 and gave the company an “overweight” rating in a research note on Wednesday, July 5th. Cowen and Company set a $147.00 price target on shares of Johnson & Johnson and gave the stock a “buy” rating in a research report on Thursday, August 24th. UBS AG reaffirmed a “buy” rating and set a $148.00 price target on shares of Johnson & Johnson in a research report on Thursday, August 31st. BidaskClub cut shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 1st. Finally, Zacks Investment Research raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Wednesday, October 4th. Four investment analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $143.70.
Shares of Johnson & Johnson (JNJ) traded down 0.02% during trading on Wednesday, hitting $141.78. The stock had a trading volume of 5,140,654 shares. Johnson & Johnson has a 52-week low of $109.32 and a 52-week high of $144.35. The firm’s 50-day moving average is $135.26 and its 200 day moving average is $131.38. The firm has a market cap of $380.54 billion, a price-to-earnings ratio of 24.66 and a beta of 0.78.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.68%. The company had revenue of $19.65 billion during the quarter, compared to analysts’ expectations of $19.29 billion. During the same period in the previous year, the company earned $1.68 EPS. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. On average, analysts expect that Johnson & Johnson will post $7.28 EPS for the current year.
WARNING: “Leerink Swann Reaffirms Outperform Rating for Johnson & Johnson (NYSE:JNJ)” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.dispatchtribunal.com/2017/10/28/johnson-johnsons-jnj-outperform-rating-reaffirmed-at-leerink-swann.html.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in JNJ. Harding Loevner LP bought a new position in Johnson & Johnson in the 2nd quarter worth about $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its position in Johnson & Johnson by 29.9% in the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after purchasing an additional 200 shares during the last quarter. Lenox Wealth Advisors Inc. grew its position in Johnson & Johnson by 0.6% in the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after purchasing an additional 5 shares during the last quarter. Mountain Capital Investment Advisors Inc bought a new position in Johnson & Johnson in the 2nd quarter worth about $124,000. Finally, Harel Insurance Investments & Financial Services Ltd. grew its position in Johnson & Johnson by 241.0% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock worth $149,000 after purchasing an additional 841 shares during the last quarter. Hedge funds and other institutional investors own 65.89% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.